Pan‐cancer analyses involving somatic mutations in 10,195 samples and mRNA expression profiles in 9850 samples from 30 solid tumors found that immune cells were more abundant in the MUC16 mutant tumor microenvironment, and MUC16 mutations were associated with immune response‐related factors associated with checkpoint inhibitor therapy [40]. Here, MUC16 is linked to neoplasm.